Menu

1 / 2

BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share

All Articles on Seeking Alpha·19 days ago
#uIEBOPmJ
Reading 0:00
15s threshold

Home

Stock Ideas

Long Ideas

Healthcare

Summary

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap.

BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera.

Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.

With 70%+ gross margins, disciplined cost controls, and robust volume growth, I rate BLLN a 'Buy' despite competitive risks and a narrow moat.

Alistair Berg/DigitalVision via Getty Images

While the emerging molecular diagnostics field has been dominated by several specialized leaders—think the likes of Natera ( NTRA ), Guardant Health ( GH ), Illumina ( ILMN ), Quest Diagnostics ( DGX ), and

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GH either through stock ownership, options, or…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.